Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 178 papers
Development of a population pharmacokinetic model for taranabant, a cannibinoid-1 receptor inverse agonist
6/2010 - Li X (Susie), Nielsen J, Cirincione B, et. al. Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist. The AAPS Journal. 2010;12(4):537-547. doi:10.1208/s12248-010-9212-2.
New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades
6/2010 - Spigelman M, Woosley R, Gheuens J. New initiative speeds tuberculosis drug development: novel drug regimens become possible in years, not decades. Int J Tuberc Lung Dis. 2010 Jun;14(6):663-4. http://www.ingentaconnect.com/content/iuatld/ijtld/2010/0000001
Global tuberculosis drug development pipeline: the need and the reality
5/2010 - Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet. 2010 Jun 12;375(9731):2100-9. doi: 10.1016/S0140-6736(10)60359-9.
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients (AAC01354-09)
5/2010 - Diacon AH, Dawson R, Hanekom M, et. al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7. doi: 10.1128/AAC.01354-09.
Tuberculosis drug development: Progress, challenges, and the road ahead
4/2010 - Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis (Edinb). 2010 May;90(3):162-7. doi: 10.1016/j.tube.2010.03.003.
Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships
1/2010 - Brooks AD, Wells WA, McLean TD, et. al. Ensuring that Developing Countries have Access to New Healthcare Products: The Role of Product Development Partnerships. 2010. Innovation Strategy Today 2010 Jan. 3:1-5.
Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
1/2010 - Palmer BD, Thompson AM, Sutherland HS, et. al. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem. 2010 Ja
Toward an Optimized Therapy for Tuberculosis? Drugs in Clinical Trials and in Preclinical Development
12/2009 - Ma Z, Lienhardt C. Toward an optimized therapy for tuberculosis? Drugs in clinical trials and in preclinical development. Clin Chest Med. 2009 Dec;30(4):755-68, ix. doi: 10.1016/j.ccm.2009.08.011.
Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent
11/2009 - Maroz A, Shinde SS, Franzblau SG, et. al. Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent. Org Biomol Chem. 2010 Jan 21;8(2):413-8. doi: 10.1039/b915877d.
Assessment of global capacity to conduct tuberculosis drug development trials- do we have what it takes
11/2009 - van Niekerk C, Ginsberg A. Assessment of global capacity to conduct tuberculosis drug development trials: do we have what it takes? Int J Tuberc Lung Dis. 2009 Nov;13(11):1367-72. http://www.ingentaconnect.com/content/iuatld/ijtld/2009/00000013/00000011/a
Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase
10/2009 - Haque TS, Liang N, Golla R, et. al. Potent biphenyl- and 3-phenyl pyridine-based inhibitors of acetyl-CoA carboxylase. Bioorg Med Chem Lett. 2009 Oct 15;19(20):5872-6. doi: 10.1016/j.bmcl.2009.08.077.
Synthesis and Structure-activity Relationships of Antitubercular 2-Nitroimidazooxazines Bearing Heterocyclic Side Chains
9/2009 - Sutherland HS, Blaser A, Kmentova I, et. al. Synthesis and structure-activity relationships of antitubercular 2-nitroimidazooxazines bearing heterocyclic side chains. J Med Chem. 2010 Jan 28;53(2):855-66. doi: 10.1021/jm901378u.
Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on
6/2009 - Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK. Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3726-33. doi: 10.1128/AAC.00112-09
Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
6/2009 - Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman, MK. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother. 2009 Sep;53(9):3720-5. doi: 10.1128/AAC.00106-09.
Acid Resistance in Mycobacterium tuberculosis
5/2009 - Vandal OH, Nathan CF, Ehrt S. Acid resistance in Mycobacterium tuberculosis. J Bacteriol. 2009 Aug;191(15):4714-21. doi: 10.1128/JB.00305-09.
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis
2/2009 - Rosenthal IM, Tasneen R, Peloquin CA, et. al. Dose-Ranging Comparison of Rifampin and Rifapentine in Two Pathologically Distinct Murine Models of Tuberculosis. Antimicrob Agents Chemother. 2012 Aug; 56(8): 4331–4340. doi: 10.1128/AAC.00912-12
Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug PA-824
2/2009 - Thompson AM, Blaser A, Anderson RF, et. al. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J
Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment
11/2008 - Vandal OH, Roberts JA, Odaira T, Schnappinger D, Nathan CF, Ehrt S. Acid-susceptible mutants of Mycobacterium tuberculosis share hypersusceptibility to cell wall and oxidative stress and to the host environment. J Bacteriol. 2009 Jan;191(2):625-31. doi: 1
Estimating the market for tuberculosis drugs in industrialized and developing nations
10/2008 - Schwalbe NR, Wells WA, Geaneotes AP, et. al. Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis. 2008 Oct;12(10):1173-81. http://www.ingentaconnect.com/content/iuatld/ijtld/2008/00000012/00000010/a
Emerging Drugs for Active Tuberculosis
10/2008 - Ginsberg AM. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med. 2008 Oct;29(5):552-9. doi: 10.1055/s-0028-1085706.